Recombinant Anti-Cytokeratin 5 antibody [EPR1600Y] (ab75869)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR1600Y] to Cytokeratin 5
- Suitable for: WB, IHC-P, ICC/IF, Flow Cyt (Intra)
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Cytokeratin 5 antibody [EPR1600Y]
See all Cytokeratin 5 primary antibodies -
Description
Rabbit monoclonal [EPR1600Y] to Cytokeratin 5 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-P, ICC/IF, Flow Cyt (Intra)more details
Unsuitable for: IP -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide corresponding to Human Cytokeratin 5.
Database link: P13647 -
Positive control
- A431 cell lysate and human squamous cervical carcinoma tissue. IHC-P: human normal cervix tissue.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. -
Dissociation constant (KD)
KD = 3.19 x 10 -10 M Learn more about KD -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR1600Y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab75869 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (1) |
1/10000 - 1/50000. Detects a band of approximately 62 kDa (predicted molecular weight: 62 kDa).
|
IHC-P |
1/100 - 1/1000. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
|
ICC/IF |
1/100 - 1/500.
|
|
Flow Cyt (Intra) |
Use at an assay dependent concentration.
|
Notes |
---|
WB
1/10000 - 1/50000. Detects a band of approximately 62 kDa (predicted molecular weight: 62 kDa). |
IHC-P
1/100 - 1/1000. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
ICC/IF
1/100 - 1/500. |
Flow Cyt (Intra)
Use at an assay dependent concentration. |
Target
-
Involvement in disease
Defects in KRT5 are a cause of epidermolysis bullosa simplex Dowling-Meara type (DM-EBS) [MIM:131760]. DM-EBS is a severe form of intraepidermal epidermolysis bullosa characterized by generalized herpetiform blistering, milia formation, dystrophic nails, and mucous membrane involvement.
Defects in KRT5 are the cause of epidermolysis bullosa simplex with migratory circinate erythema (EBSMCE) [MIM:609352]. EBSMCE is a form of intraepidermal epidermolysis bullosa characterized by unusual migratory circinate erythema. Skin lesions appear from birth primarily on the hands, feet, and legs but spare nails, ocular epithelia and mucosae. Lesions heal with brown pigmentation but no scarring. Electron microscopy findings are distinct from those seen in the DM-EBS, with no evidence of tonofilament clumping.
Defects in KRT5 are a cause of epidermolysis bullosa simplex Weber-Cockayne type (WC-EBS) [MIM:131800]. WC-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering limited to palmar and plantar areas of the skin.
Defects in KRT5 are a cause of epidermolysis bullosa simplex Koebner type (K-EBS) [MIM:131900]. K-EBS is a form of intraepidermal epidermolysis bullosa characterized by generalized skin blistering. The phenotype is not fundamentally distinct from the Dowling-Meara type, althought it is less severe.
Defects in KRT5 are the cause of epidermolysis bullosa simplex with mottled pigmentation (MP-EBS) [MIM:131960]. MP-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering at acral sites and 'mottled' pigmentation of the trunk and proximal extremities with hyper- and hypopigmentation macules.
Defects in KRT5 are the cause of Dowling-Degos disease (DDD) [MIM:179850]; also known as Dowling-Degos-Kitamura disease or reticulate acropigmentation of Kitamura. DDD is an autosomal dominant genodermatosis. Affected individuals develop a postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails. -
Sequence similarities
Belongs to the intermediate filament family. - Information by UniProt
-
Database links
- Entrez Gene: 3852 Human
- Omim: 148040 Human
- SwissProt: P13647 Human
- Unigene: 433845 Human
-
Alternative names
- 58 kDa cytokeratin antibody
- CK-5 antibody
- CK5 antibody
see all
Images
-
IHC image of Cytokeratin 5 staining in a section of formalin-fixed paraffin-embedded normal human cervix* performed on a Leica Biosystems BOND® RX instrument. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab78569, 0.1ug/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset secondary-only control image is taken from an identical assay without primary antibody.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre -
Fluorescent immunohistochemical analysis of paraffin-embedded human cervical carcinoma tissue using unpurified ab75869. Green-CK5 red-PI
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
Immunocytochemistry/Immunofluorescence analysis of A431 (human epidermoid carcinoma) cells labelling Cytokeratin 5 with purified ab75869 at 1/100. Cells were fixed with 4% Paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. The cells were co-stained with ab7291, a mouse anti-tubulin antibody (1/1000) using ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/1000) as the secondary. Nuclei couterstained with DAPI (blue).
For negative control 1, rabbit primary antibody was used, followed by anti-mouse secondary antibody (ab150120). For negative control 2, mouse primary antibody (ab7291) was used followed by anti-rabbit secondary antibody (ab150077).
-
All lanes : Anti-Cytokeratin 5 antibody [EPR1600Y] (ab75869) at 1/1000 dilution
Lane 1 : N-GST tagged full-length recombinant human Cytokeratin 6A Protein, 10 ng
Lane 2 : N-GST tagged full-length recombinant human Cytokeratin 5 protein, 10 ng
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 62 kDa
Observed band size: 87 kDa why is the actual band size different from the predicted?
Exposure time: 10 secondsBlocking buffer: 5% NFDM/TBST.
-
All lanes : Anti-Cytokeratin 5 antibody [EPR1600Y] (ab75869) at 1/50000 dilution (purified)
Lane 1 : A431 (human epidermoid carcinoma) whole cell lysate
Lane 2 : HACAT (human keratinocyte) whole cell lysate
Lane 3 : Human skin tissue lysate
Lane 4 : Human fetal tonsil tissue lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 62 kDa
Observed band size: 62 kDa
Blocking and diluting buffer 5% NFDM/TBST -
Intracellular Flow Cytometry analysis of A431 (human epidermoid carcinoma) cells labeling Cytokeratin 5 with purified ab75869 at 1/20 dilution (10ug/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluor® 488) (1/2000 dilution) was used as the secondary antibody. Rabbit monoclonal IgG (Black) was used as the isotype control, cells without incubation with primary antibody and secondary antibody (Blue) was used as the unlabeled control.
-
Anti-Cytokeratin 5 antibody [EPR1600Y] (ab75869) at 1/10000 dilution (unpurified) + A431 cell lysate at 10 µg
Secondary
goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 62 kDa
Observed band size: 62 kDa -
Immunohistochemical analysis of paraffin embedded human tonsil tissue section labelling Cytokeratin 5 with purified ab75869 at dilution of 1/1000. The secondary antibody used was HRP-conjugated Goat Anti-Rabbit IgG H&L (ab97051) at dilution of 1/500. The sample was counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control and is shown in the inset.
-
Unpurified ab75869 at 1/100 dilution staining Cytokeratin 5 in human squamous cervical carcinoma by Immunohistochemistry, Paraffin-embedded tissue.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
Fluorescent immunohistochemical analysis of paraffin-embedded human cervical carcinoma using unpurified ab75869. Green-CK5 red-PI.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (24)
ab75869 has been referenced in 24 publications.
- Li Z et al. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nat Commun 13:2011 (2022). PubMed: 35440136
- Itou J et al. Supplementation with Fermented Barley Extract Prevents Mammary Epithelial Cell Invasion in an Early Breast Cancer Model. Acta Histochem Cytochem 54:73-78 (2021). PubMed: 34012179
- Finlay-Schultz J et al. New generation breast cancer cell lines developed from patient-derived xenografts. Breast Cancer Res 22:68 (2020). PubMed: 32576280
- Luo P et al. s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide. Cell Res 30:779-793 (2020). PubMed: 32296111
- Sprott RF et al. Flagellin shifts 3D bronchospheres towards mucus hyperproduction. Respir Res 21:222 (2020). PubMed: 32847538